Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination

[1]  S. Ménard,et al.  p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma , 2000, International journal of cancer.

[2]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[3]  A. Krieg,et al.  The role of CpG motifs in innate immunity. , 2000, Current opinion in immunology.

[4]  M. Campiglio,et al.  Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.

[5]  P. Musiani,et al.  Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.

[6]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[7]  S. Ménard,et al.  Correspondence re: Y. Chen et al., DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors. Cancer Res., 58: 1965-1971, 1998. , 1999, Cancer research.

[8]  M. Cilli,et al.  DNA vaccination against the ovarian carcinoma-associated antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in mice , 1999, Cancer Gene Therapy.

[9]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  B. Groner,et al.  Protection against mammary tumor growth by vaccination with full‐length, modified human ErbB‐2 DNA , 1999, International journal of cancer.

[11]  L. Esserman,et al.  Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice , 1999, Cancer Immunology, Immunotherapy.

[12]  A. Chalian,et al.  Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine , 1998, Oncogene.

[13]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[14]  S. Ménard,et al.  Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation , 1998, Oncogene.

[15]  C. Figdor,et al.  Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. , 1998, Cancer research.

[16]  T. Kipps,et al.  DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. , 1998, Cancer research.

[17]  S. Ménard,et al.  High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Provinciali,et al.  Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA , 1997, Cancer Immunology, Immunotherapy.

[19]  M. Cheever,et al.  HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. , 1997, Advances in cancer research.

[20]  I. Cohen,et al.  Suppressive vaccination with DNA encoding a variable region gene of the T–cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity , 1996, Nature Medicine.

[21]  M. Colston,et al.  Vaccination against tuberculosis by DNA injection , 1996, Nature Medicine.

[22]  E. Raz,et al.  Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Gralow,et al.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.

[24]  J. Taylor‐Papadimitriou,et al.  Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1‐expressing syngeneic mouse tumour cells , 1996, International journal of cancer.

[25]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[26]  F. Liew,et al.  Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. , 1995, Immunology.

[27]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Raz,et al.  Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Schlom,et al.  Immune response to a carcinoembryonic antigen polynucleotide vaccine. , 1994, Cancer research.

[30]  S. Ménard,et al.  Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. , 1993, Cancer research.

[31]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[33]  M. Campiglio,et al.  Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification , 1991, International journal of cancer.